Randomized, double-blind, placebo-controlled study of tremelimumab for second-and third-line treatment of unresectable pleural or peritoneal mesothelioma

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: a7d32f9215c900d56f96b583e3a04ebd3028a837
First added on: Feb 06, 2025